Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Director departure
|
|
INTEGRATED BIOPHARMA INC (INBP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/17/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 02/10/2023 |
8-K
| Quarterly results |
| 12/06/2022 |
8-K
| Quarterly results |
| 11/28/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/24/2022 |
8-K
| Quarterly results |
| 09/14/2022 |
8-K
| Quarterly results |
| 07/15/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 02/10/2022 |
8-K
| Quarterly results |
| 11/29/2021 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 11/10/2021 |
8-K
| Quarterly results |
| 09/02/2021 |
8-K
| Quarterly results |
| 07/07/2021 |
8-K
| Termination of a Material Definitive Agreement |
| 05/13/2021 |
8-K
| Quarterly results |
| 04/08/2021 |
8-K
| Quarterly results |
| 02/12/2021 |
8-K
| Quarterly results |
| 01/22/2021 |
8-K
| Other Events |
| 11/30/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/12/2020 |
8-K
| Quarterly results|
Docs:
|
"Integrated BioPharma Reports Results for its Quarter Ended September 30, 2020 HILLSIDE, NEW JERSEY - Integrated BioPharma, Inc. reports its financial results for the quarter ended September 30, 2020. Revenue for the quarter ended September 30, 2020 was $15.2 million compared to $11.4 million for the quarter ended September 30, 2019, an increase of $3.8 million or 33.0%. The Company had operating income for the quarter ended September 30, 2020 of $1.5 million compared to operating income of $0.5 million for the quarter ended September 30, 2019. For the quarter ended September 30, 2020, the Company had net income of $1.0 million or $0.04 per share of common stock, compared with net income of $0.3 million or $0.01 per share of common stock for the quarter ended September 30, 2019. The Compan..." |
|
| 11/09/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/24/2020 |
8-K
| Quarterly results |
| 05/13/2020 |
8-K
| Quarterly results|
Docs:
|
"Integrated BioPharma Reports Results for its Quarter Ended March 31, 2020 HILLSIDE, NEW JERSEY - Integrated BioPharma, Inc. reports its financial results for the quarter ended March 31, 2020. Revenue for the quarter ended March 31, 2020 was $13.6 million compared to $14.1 million for the quarter ended March 31, 2019, a decrease of $0.5 million or 3.5%. The Company had operating income for the quarter ended March 31, 2020 of $1.9 million compared to operating income of $1.2 million for the quarter ended March 31, 2019. Revenues for the nine-month period ended March 31, 2020 were $39.2 million compared to $36.4 million for the nine-month period ended March 31, 2019, an increase of $2.8 million or 7.7%. The Company had operating income for the nine-month period ended March 31, 2020 of $2.6 m..." |
|
| 02/12/2020 |
8-K
| Quarterly results |
| 12/03/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/13/2019 |
8-K
| Quarterly results |
| 09/16/2019 |
8-K
| Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant|
Docs:
|
"Integrated BioPharma Reports Results for its Fiscal Year Ended June 30, 2019 HILLSIDE, NEW JERSEY - Integrated BioPharma, Inc. reported financial results for the fiscal year ended June 30, 2019 on August 29, 2019. Revenues for the fiscal year ended June 30, 2019 were $50.0 million compared to $43.7 million for the fiscal year ended June 30, 2018, an increase of $6.3 million or 14.4%. The Company had operating income for the fiscal year ended June 30, 2019 of $2.7 million compared to operating income of $1.7 million for the fiscal year ended June 30, 2018. For the fiscal year ended June 30, 2019, the Company had net income of $1.7 million or $0.06 per share of common stock, compared with net income of $0.7 million or $0.03 per share of commons stock for the fiscal year ended June 30, 2018...." |
|
| 05/29/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2019 |
8-K
| Quarterly results|
Docs:
|
"Integrated BioPharma Reports Results for its Quarter Ended March 31, 2019 and Announces Refinancing of its Senior Credit Facility with PNC Bank, National Association HILLSIDE, NEW JERSEY - Integrated BioPharma, Inc. reported financial results today for the three and nine-month periods ended March 31, 2019 and the refinancing of our Senior Credit Facility. Revenues for the quarter ended March 31, 2019 were $14.1 million compared to $10.6 million for the quarter ended March 31, 2018, an increase of $3.5 million or 33.2%. The Company had operating income for the quarter ended March 31, 2019 of $1.2 million compared to operating income of $0.7 million for the quarter ended March 31, 2018. Revenues for the nine-month period ended March 31, 2019 were $36.4 million compared to $31.1 million for ..." |
|
| 05/06/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/26/2018 |
8-K
| Submission of Matters to a Vote of Security Holders |
|
|
|